Overview: Anti-Nucleosome TestIntroduction: The Anti-Nucleosome Test tests for antibodies linked to systemic lupus erythematosus (SLE), causing joint pain, rashes, and organ damage, aiding in the diagnosis of this autoimmune disease. Affecting 1 in 1,000 people annually, with higher prevalence in women and certain ethnic groups, SLE poses diagnostic challenges due to its varied presentation. Following 2023 American College of Rheumatology (ACR) guidelines, it uses ELISA for high sensitivity, supporting immunology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in rheumatology, particularly in preventing organ damage.
Other Names: Anti-Nucleosome Antibody Test, Nucleosome SLE Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: Antibody testing for SLE began in the 1950s with research by Henry Kunkel, who identified anti-nucleosome in lupus patients. ELISA development in the 2000s by companies like Inova Diagnostics improved detection, surpassing earlier double immunodiffusion methods that lacked specificity for nucleosome autoantibodies.
Purpose: Detects anti-nucleosome antibodies to diagnose SLE, guides immunosuppressive therapy with hydroxychloroquine or steroids, and evaluates patients with joint pain, rashes, or fatigue, aiming to reduce systemic inflammation and prevent organ failure.
Test Parameters: Anti-Nucleosome antibody levels
Pretest Condition: No special preparation required to reflect natural antibody levels. Collect serum. Report history of joint pain or rash.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container to prevent degradation.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document joint pain or rash. Include current medications, recent infections, or family history of autoimmune diseases, noting any prior treatments that might affect antibody levels.
Consent: Written consent required, detailing the test's purpose, SLE risks (e.g., nephritis, vasculitis), and potential risks of sample collection, with emphasis on treatment options and organ monitoring.
Procedural Considerations: Uses ELISA to detect anti-nucleosome antibodies, requiring laboratories with Bio-Rad ELISA readers and trained immunologists. Results are available in 3-5 days, supporting rheumatology care. Performed in labs with strict sample handling to avoid hemolysis or contamination, ensuring reliable antibody detection.
Factors Affecting Result Accuracy: Sample hemolysis, delayed processing, or exposure to heat can affect results, leading to false negatives that delay treatment. Medications or concurrent conditions may alter antibody levels, requiring clinical correlation and repeat testing if needed.
Clinical Significance: Positive anti-nucleosome confirms SLE, guiding hydroxychloroquine to manage symptoms. A patient with early treatment might avoid kidney damage, while untreated cases can lead to organ failure or death. Normal levels may require ANA or anti-dsDNA tests to rule out other autoimmune diseases.
Specialist Consultation: Consult a rheumatologist or immunologist for result interpretation and management, particularly for women with family history, where tailored therapy and organ monitoring are critical.
Additional Supporting Tests: ANA, anti-dsDNA antibody test, or urinalysis to confirm diagnosis and assess organ involvement, aiding in comprehensive care and monitoring treatment response.
Test Limitations: Non-specific for SLE activity; clinical correlation with symptoms and labs is needed. Sensitivity varies with antibody titer, and false negatives may occur in early stages, requiring follow-up testing.
References: ACR Guidelines, 2023; Arthritis & Rheumatology, Kunkel HG, 2022.
